Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 4, 2010, Pages 371-374

  Sakr, Rita A ^a   Barbashina, Violetta ^a   Morrogh, Mary ^a   Chandarlapaty, Sarat ^a   Andrade, Victor P ^a   Arroyo, Crispinita D ^a   Olvera, Narciso ^a   King, Tari A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

automated protocol; breast cancer; immunohistochemistry; PTEN protein expression

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

AUTOMATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PARAFFIN EMBEDDING; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 77954144291     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181d50bd5     Document Type: Article

References (12)

1. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947.
2. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362.
3. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004;15:171-176.
4. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997;57:3657-3659.
5. Garcia JM, Silva J, Pena C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004;41:117-124.
6. Bose S, Crane A, Hibshoosh H, et al. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33: 405-409.
7. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127.
8. Faratian D, Goltsov A, Lebedeva G, et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009; 69:6713-6720.
9. Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology. 2005;68:398-404.
10. Lee JI, Soria JC, Hassan KA, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg. 2001;127:1441-1445.
11. Thomas GV, Horvath S, Smith BL, et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004;10:8351-8356.
12. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260.